Supplementary Data from Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition

suppl figures 1-6. SF1: Myt1 knockdown sensitizes breast cells to Adavosertib; SF2: Wee1 knockdown mimics Adavosertib treatment; SF3: Adavosertib does not inhibit Myt1 activity; SF4: Adavosertib resistant cells do not prematurely enter mitosis; SF5: Adavosertib induced mitotic exit delays occur in cells with and without abnormal chromosome condensation and spindle organization; SF6: Myt1 but not Wee1 is associated with a worse clinical outcome. Suppl. Table 1. p53 and molecular subtypes of breast cell lines. * indicate non-tumorigenic cell lines; Suppl Table 2. Cell line sensitive to Adavosertib in the presence of siSc or siMyt1; Suppl Table 3. Cdk1 inhibition prevents centromere fragmentation